Mazdutide GLORY-2 reports up to 20.1% weight loss in Chinese adults with obesity

Innovent Biologics said its Phase 3 GLORY-2 trial of mazdutide, an experimental dual glucagon/GLP-1 receptor agonist, met its main goal and all key secondary goals in Chinese adults with obesity ^[1]. The company plans to file for approval of the 9 mg dose for weight management with China's drug regulator soon ^[1].

GLORY-2 enrolled 462 adults with obesity, including some with type 2 diabetes, and randomly assigned them 2:1 to mazdutide 9 mg or placebo for 60 weeks, on top of lifestyle changes ^[1]. Participants started at an average weight of 94.0 kg and average BMI of 34.3 ^[1]. At week 60, the mazdutide group lost an average of 18.55% of body weight versus 3.02% on placebo, and 44.0% of the drug group lost at least 20% of their weight compared with 2.6% on placebo ^[1]. Among participants without type 2 diabetes, average weight loss reached 20.08%, with 48.7% losing 20% or more ^[1]. Innovent says weight loss was still going down at week 60 with no plateau ^[1].

The trial also tracked liver fat, blood pressure, cholesterol, waist size and uric acid, and mazdutide beat placebo on all of these secondary measures ^[1]. In a subgroup with fatty liver at baseline, liver fat content measured by MRI dropped 71.9% on mazdutide versus 5.1% on placebo ^[1]. Side effects were mostly mild-to-moderate stomach and gut problems, and 2.9% of the mazdutide group stopped treatment because of side effects, versus none on placebo ^[1].

Innovent also pointed to a separate Chinese Phase 3 study, called DREAMS-3, that compares mazdutide against semaglutide in adults with type 2 diabetes and obesity, and says mazdutide outperformed semaglutide on both blood sugar and weight measures ^[1]. A related trial, GLORY-3, is comparing mazdutide against 2.4 mg semaglutide in people with overweight or obesity and fatty liver disease, but that study is still running and has not reported results ^[1]. Innovent has completed or is running seven Phase 3 studies of mazdutide in China, covering obesity, type 2 diabetes, and other conditions ^[1]. Mazdutide already has NMPA approval in China for chronic weight management and for glycemic control in type 2 diabetes, under specific BMI and treatment criteria ^[1].

Why it matters for patients

Mazdutide is not approved or available in the United States, and the sources do not describe any US regulatory filing or timeline ^[1]. For US readers already using semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), this is a signal about where the GLP-1 drug class is heading, not a treatment option they can access now. The trial results come from a company press release describing a Chinese regulatory submission, not from a peer-reviewed publication or an FDA review, so independent verification of the numbers is not yet available in these sources.

The reported weight-loss numbers, up to 20.1% at 60 weeks in people without diabetes, are in a similar range to some existing approved GLP-1 and dual-agonist drugs, but a direct, independently reviewed comparison is not established here ^[1]. The claim that mazdutide beat semaglutide in a head-to-head China study is also based on the company's own summary, and specific comparative numbers from that trial are not included in these sources ^[1].

What happens next

Innovent says it plans to submit the mazdutide 9 mg new drug application to China's National Medical Products Administration "in the near term," without giving an exact date ^[1]. Two Phase 3 studies, GLORY-3 and GLORY-OSA, are still ongoing, and mazdutide is also being tested in adolescents with obesity and in patients with fatty liver disease and heart failure with preserved ejection fraction, though none of these have reported results yet ^[1]. Whether or when mazdutide might be studied or filed for approval in the United States is not addressed in these sources.